SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 13.75 |
| Book Value / Share | n/a |
| Price / Book | n/a |
| NCAV ($M) | -0.02 |
| NCAV / Share | n/a |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.59 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.42 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.06 |
| Current Ratio | 2.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4.40 |
| Assets | 18.17 |
| Liabilities | 4.42 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -17.80 |
| Net Income | -15.49 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -14.68 |
| Cash from Investing | 0.00 |
| Cash from Financing | 15.11 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | ||
| 13D/A | Apeiron Investment Group Ltd. | 4.50 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,416 | 35,976 | 17.83 | |
| 9,931 | 49,754 | 19.96 | |
| 3,960 | 45,225 | 8.76 | |
| 19,193 | 93,489 | 20.53 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MURA – Mural Oncology plc | NAII – Natural Alternatives International, Inc. |
| NAMS – NewAmsterdam Pharma Company N.V. | NGNE – Neurogene Inc. |
| NKGN – NKGen Biotech, Inc. |
Financial data and stock pages provided by
Fintel.io